Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

January 3, 2019

Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 for the Treatment of Colorectal Cancer

December 20, 2018

Gritstone Oncology Announces Publication in Nature Biotechnology of Neoantigen Identification Capabilities of its Artificial Intelligence Platform, EDGE™

December 17, 2018

Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Antibody Therapeutics to Spearhead

December 10, 2018

Gritstone Oncology Reports Third Quarter 2018 Financial Results and Recent Business Highlights

November 14, 2018

Gritstone Oncology Announces Pricing of Initial Public Offering

September 27, 2018

bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Therapies

August 23, 2018

Gritstone Oncology Appoints Experienced Financial Executive, Steve E. Krognes, to its Board of Directors

August 9, 2018

Bristol-Myers Squibb and Gritstone Oncology Announce Clinical Research Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors

July 19, 2018

Gritstone Oncology Receives Notice of Allowance from U.S. Patent and Trademark Office on its Core Patent Application for Tumor Antigen Prediction Model

May 7, 2018

Pagination

First page
Previous page
…
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Current page 19
Page 20
Page 21
Next page
Last page

© 2024 Gritstone Bio |

Footer Links

Privacy Policy
Terms of Use
Cookie Policy
Contact

socials

Top